<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455439</url>
  </required_header>
  <id_info>
    <org_study_id>19584</org_study_id>
    <nct_id>NCT03455439</nct_id>
  </id_info>
  <brief_title>Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)</brief_title>
  <acronym>FARAONIC</acronym>
  <official_title>Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the risk factors associated with Heart Failure (HF) worsening (measured by
      hospitalizations and emergency visits because of HF exacerbations) in Spanish patients with
      Atrial Fibrilation and HF treated with rivaroxaban.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 16, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time from the baseline visit to the first hospitalization or admission to emergency services due to a Heart Failure exacerbation</measure>
    <time_frame>Up to 24 months or early termination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Date of death</measure>
    <time_frame>Up to 24 months or early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Date of all hospitalizations or admissions to emergency service</measure>
    <time_frame>Up to 24 months or early termination</time_frame>
    <description>due to a HF exacerbation or all cause</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">667</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <description>Adult patients diagnosed with Atrial Fibrilation and Heart Failure who started treatment with rivaroxaban at least 4 months prior to inclusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>As prescribed by the treating physician</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients diagnosed with Atrial Fibrilation and Heart Failure who started treatment
        with rivaroxaban at least 4 months prior to inclusion that attend the Cardiology Units or
        Internal Medicine Units at Spanish hospitals and private clinics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males and females aged 18 years or older.

          -  Patients with a diagnosis of nonvalvular Atrial Fibrilation (AF).

          -  Patients with a diagnosis of chronic Heart Failure, New York Heart Association (NYHA)
             class I-IV HF with preserved Ejection Fraction (HFpEF), HF with reduced EF (HFrEF) or
             HF with mid-range EF (HFmrEF).

          -  Patients receiving antithrombotic treatment because of AF, with rivaroxaban since at
             least 4 months before entering the study.

          -  Patients who have been given appropriate information about the study objectives and
             procedures and with the mental and physical capacity to give their informed consent to
             participate in the study.

        Exclusion Criteria:

          -  Patients participating in a research program which involves some intervention beyond
             clinical practice.

          -  Patients who started rivaroxaban after the start of the inclusion period.

          -  Patients with significate mitral stenosis or other heart valvular diseases that
             requires or have needed specific treatment (prosthesis or valvuloplasty).

          -  Patients with severe cognitive impairment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Many Locations</name>
      <address>
        <city>Multiple Locations</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 4, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

